靶向治疗对放射性碘难治性分化型甲状腺癌的疗效与安全性
该Meta分析纳入8项随机对照试验和17项单臂研究共3270例患者,评估7种靶向药物治疗放射性碘难治性分化型甲状腺癌的疗效与安全性。靶向治疗显著延长无进展生存期和总生存期,不良事件常见高血压、腹泻、蛋白尿和乏力。阿帕替尼在客观缓解率和疾病控制率方面可能表现更优。
要点
- 靶向治疗显著延长RR-DTC患者PFS(HR 0.35)和OS(HR 0.53)。
- ORR和DCR的总体风险比分别为27.63和1.66。
- 阿帕替尼在ORR(ES 0.66)和DCR(ES 0.95)方面可能表现更优。
核心结论
- 当前使用的靶向药物可显著改善RR-DTC患者的临床结局,新药阿帕替尼可能具有更优性能。
研究设计与样本
- Meta分析,纳入截至2023年9月12日检索PubMed、Embase、Cochranes和Web of Sciences的随机对照试验和单臂研究。
- 共纳入8项随机对照试验和17项单臂研究,3270例患者,涉及7种药物:凡德他尼、索拉非尼、仑伐替尼、卡博替尼、阿帕替尼、多纳非尼和安罗替尼。
主要发现
- 靶向治疗显著延长PFS,总体风险比为0.35(95%CI 0.23-0.53,P<.00001)。
- 靶向治疗显著延长OS,总体风险比为0.53(95%CI 0.32-0.86,P<.00001)。
- ORR的总体风险比为27.63(95%CI 12.39-61.61,P<.00001),DCR的总体风险比为1.66(95%CI 1.48-1.86,P<.00001)。
- 亚组分析显示阿帕替尼对ORR的效应量(ES)为0.66(95%CI 0.49-0.83,P<.00001),对DCR的ES为0.95(95%CI 0.91-1.00,P<.00001)。
- 常见药物不良事件包括高血压、腹泻、蛋白尿和乏力。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: There has been considerable success in the development of drugs for targeted therapy of radioiodine-refractory differentiated thyroid cancer (RR-DTC) and to know the safety and efficacy of these drugs will help their appropriate application. OBJECTIVE: To evaluate the efficacy and safety of current targeted drug therapies for radioiodine-refractory differentiated thyroid cancer. METHODS: This was a meta-analysis of relevant randomized controlled trials (RCTs) and single-arm studies searched across PubMed, Embase, Cochranes, and Web of Sciences up to September 12, 2023. Stata15.0 software was used to assess overall survival (OS), progression-free survival (PFS), disease control rate (DCR), objective response rate (ORR), and adverse events. The Cochrane Bias Risk tool was used to assess literature quality and trial bias and RevMan 5.4 was used to generate a quality assessment map. RESULTS: A total of 8 RCTs and 17 single-arm studies with 3270 patients on 7 drugs-vandetanib, sorafenib, lenvatinib, cabozantinib, apatinib, donafenib, and anlotinib-were included. Targeted therapy with these drugs effectively prolonged PFS and OS in patients with RR-DTC with overall hazard ratios of 0.35 (95% CI 0.23-0.53, P < .00001) and 0.53 (95% CI 0.32-0.86, P < .00001), respectively. ORR and DCR were also prolonged, with overall risk ratios of 27.63 (95% CI 12.39-61.61, P < .00001) and 1.66 (95% CI 1.48-1.86, P < .00001), respectively. The subgroup analysis using effect size (ES) showed that apatinib had the best effect on ORR with an ES of 0.66 (95% CI 0.49-0.83, P < .00001) and DCR with a ES of 0.95 (95% CI 0.91-1.00, P < .00001). Common drug adverse events included hypertension, diarrhea, proteinuria, and fatigue. CONCLUSION: The currently used targeted drug therapies for RR-DTC can significantly improve clinical outcomes, and the new drug apatinib demonstrates promise for potentially superior performance.
引用
- Zhang Y, Zhang X, Lin L, et al. Efficacy and Safety of Targeted Therapy for Radioiodine-Refractory Differentiated Thyroid Cancer. J Clin Endocrinol Metab. 2025. PMID: 39292866. doi:10.1210/clinem/dgae617
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。